Table 4. Evaluation of immune response and clinical outcome after therapeutic cancer vaccines by Cox proportional hazards model.

Product	Cancer	Phase	Evaluation results	Positive association	Reference
Canvaxin®	Melanoma (Stage IV)	P II	Elevated anti-TA90 IgM and strong DTH to vaccine correlated with improved survival (p = 0.03 and 0.008, respectively).	Y	30
	Melanoma (Stage II)	P II	Anti-TA90 IgM was identified as an independent prognostic factor for OS and DFS.	Y	30
	Melanoma (Stage IIIa, IV)	After P II	It was revealed prognostic significance for site of metastases (p = 0.0001) and immunotherapy (p = 0.0001).	Y	31
M-VaxTM	Melanoma (Stage III)	Before P III	The failure to develop DTH to unmodified autologous melanoma cells was associated with OS (HR = 2.54, p = 0.080). After adjustment for age only, the hazards ratios for RFS and OS increased and were statistically significant (p = 0.029 and 0.036, respectively).	Y	36
		P III	A positive DTH response to unmodified tumor cells remained statistically significant for both RFS and OS (p = 0.015 and 0.009, respectively).	Y	13
MyVax®	Non-Hodgkin's lymphoma	Before P III	Valine/valine genotype and humoral immune response were independent positive predictors for PFS (p = 0.0013 and 0.0015, respectively).	Y	37